Skip to main content

Table 7 Carrier study exploratory clinical efficacy assessments: change from parent study baseline to extension week 52

From: Long-term safety and tolerability of bapineuzumab in patients with Alzheimer’s disease in two phase 3 extension studies

 

3003 ApoE ε4 carrier study

PBO + BAP 0.5 (n = 199)

BAP 0.5 + BAP 0.5 (n = 256)

ADAS-Cog, LS mean (SE)

10.12 (0.75)

10.11 (0.63)

 LS mean difference

0.00; P = 0.996

DAD, LS mean (SE)

–20.96 (1.65)

–22.72 (1.36)

 LS mean difference

–1.75; P = 0.412

NPI, LS mean (SE)

4.32 (0.96)

3.52 (0.80)

 LS mean difference

–0.80; P = 0.524

MMSEa, LS mean (SE)

–4.44 (0.26)

–4.26 (0.21)

 LS mean difference

0.18; P = 0.598

  1. ADAS-Cog Alzheimer’s Disease Assessment Scale—Cognitive Subscale, ApoE apolipoprotein E, BAP bapineuzumab, DAD Disability Assessment Scale for Dementia, LS least squares, MMSE Mini-Mental State Examination, NPI Neuropsychiatric Inventory, PBO placebo, SE standard error of the mean
  2. aDifference in MMSE score was between parent study baseline and extension study week 45
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193